Lifevantage Revenue Growth Rates (LFVN), Current and Historic Growth - CSIMarket
CSIMarket
 


Lifevantage Corp  (NASDAQ: LFVN)
 

LFVN's Revenue Growth by Quarter and Year

Lifevantage's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LFVN/growth
https://api.csimarket.com/api/v1/companies/LFVN/fundamentals
https://api.csimarket.com/api/v1/companies/LFVN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
LFVN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 37.12
FY 37.12

LFVNs Annual Revenue
Lifevantage's Revenue in the fiscal year 2026 $ 182.59 millions
Lifevantage's Revenue in the fiscal year 2025 $ 227.67 millions
Lifevantage's Revenue in the fiscal year 2024 $ 199.72 millions
Lifevantage's Revenue in the fiscal year 2023 $ 213.01 millions
Lifevantage's Revenue in the fiscal year 2022 $ 206.36 millions




LFVN Revenue first quarter 2026 Y/Y Growth Comment
Lifevantage Corp reported decline in Revenue in the first quarter 2026 by -20.72% to $ 37.12 millions, from the same quarter in 2025.
The contraction in the first quarter 2026 Lifevantage Corp's Revenue compares unfavorably to the Company's average Revenue rise of 20.41%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 166 other companies have achieved higher Revenue growth. While Lifevantage Corp' s Revenue fall of -20.72% ranks overall at the positon no. 3609 in the first quarter 2026.




LFVN Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September -20.72 %
FY   -

Financial Statements
Lifevantage's first quarter 2026 Revenue $ 37.12 millions LFVN's Income Statement
Lifevantage's first quarter 2025 Revenue $ 46.82 millions Quarterly LFVN's Income Statement


LFVN Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September -12.42 %
FY (Year on Year)   -




Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #167
Healthcare Sector #493
Overall #3609

Revenue Y/Y Growth Statistics
High Average Low
263.02 % 20.41 % -28.65 %
(Sep 30 2016)   (Jun 30 2026)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #167
Healthcare Sector #493
Overall #3609
Revenue Y/Y Growth Statistics
High Average Low
263.02 % 20.41 % -28.65 %
(Sep 30 2016)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Lifevantage's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
50.78 % 3.83 % -14.96 %
(Jun 30 2011)  


LFVN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Lifevantage Corp disclosed drop in Revenue from the fourth quarter by -12.42% to $ 37.12 millions, from $ 42.38 millions achived in the previous reporting period.

But that's not important problem, as Lifevantage's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 97 other companies have achieved higher Revenue quarter on quarter growth. While Lifevantage's Revenue growth quarter on quarter, overall rank is 2200.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #98
Healthcare Sector #279
Overall #2200
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #98
Healthcare Sector #279
Overall #2200
Revenue Q/Q Growth Statistics
High Average Low
50.78 % 3.83 % -14.96 %
(Jun 30 2011)  


LFVN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Lifevantage Corp disclosed drop in Revenue from the fourth quarter by -12.42% to $ 37.12 millions, from $ 42.38 millions achived in the previous reporting period.

But that's not important problem, as Lifevantage's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 97 other companies have achieved higher Revenue quarter on quarter growth. While Lifevantage's Revenue growth quarter on quarter, overall rank is 2200.


Lifevantage's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)
12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 171.25
Y / Y Revenue Growth (TTM) -24.81 %
Year on Year Revenue Growth Overall Ranking # 1181
Seqeuential Revenue Change (TTM) -5.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 2340


Cumulative Revenue growth Comment
Lifevantage's cumulative 12 months Revenue continue to fall, but on the faster rate at -24.81% year on year, at Sep 30 2026 compare to the -20.52% decrease at Jun 30 2026. If the Lifevantage's fiscal year would end at Sep 30 2026, annual Revenue would be $171 millions.

In the Healthcare sector 212 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1181, from total ranking in previous quarter at 1353.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 213
Overall # 1181

Revenue TTM Y/Y Growth Statistics
High Average Low
224.21 %
14.31 %
-20.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 336
S&P 500 # 2340
Cumulative Revenue growth Comment
Lifevantage's cumulative 12 months Revenue continue to fall, but on the faster rate at -24.81% year on year, at Sep 30 2026 compare to the -20.52% decrease at Jun 30 2026. If the Lifevantage's fiscal year would end at Sep 30 2026, annual Revenue would be $171 millions.

In the Healthcare sector 212 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1181, from total ranking in previous quarter at 1353.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 213
Overall # 1181

Revenue TTM Y/Y Growth Statistics
High Average Low
224.21 %
14.31 %
-20.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 336
S&P 500 # 2340




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LFVN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Nuwellis Inc -0.23%$ -0.226 millions
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions


About Lifevantage Revenue Growth Rates (LFVN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lifevantage Corp (CIK 849146).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-453560
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lifevantage Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.